Loading organizations...
§ Private Profile · Tel Aviv, Israel
Sight Diagnostics is a technology company.
Sight Diagnostics develops and commercializes AI-powered blood diagnostic devices that provide rapid, lab-grade results. Their flagship OLO device utilizes advanced computer vision and machine learning algorithms to analyze a few drops of blood from a finger prick, performing comprehensive blood counts and other critical tests. This technology streamlines the diagnostic process by decoding live immune cells, enabling quicker insights into patient health conditions directly at the point of care.
The company was co-founded in 2010 by Yosi Pollak, a leader in machine vision technology, and Daniel Levner, an artificial intelligence expert from Harvard’s Wyss Institute. They recognized the potential to revolutionize traditional blood testing by applying sophisticated AI and imaging to overcome the limitations of conventional laboratory analysis, aiming to make diagnostics more accessible and efficient.
Sight Diagnostics’ products serve clinics, hospitals, and other healthcare providers, bringing essential diagnostic capabilities closer to patients. The company’s vision centers on expanding disease detection and improving patient outcomes through smarter, more accessible blood testing, ultimately striving to integrate advanced diagnostics seamlessly into everyday clinical practice.
Sight Diagnostics has raised $149.0M across 6 funding rounds.
Sight Diagnostics has raised $149.0M in total across 6 funding rounds.
Sight Diagnostics has raised $149.0M across 6 funding rounds. Most recently, it raised $71.0M Series D in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2020 | $71M Series D | DAN Eldar | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, Kobi Marenko, Chase Koch | Announced |
| Feb 1, 2019 | $28M Series C | — | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, Kobi Marenko | Announced |
| Jul 12, 2018 | $25M Venture Round | Eric Schmidt | — | Announced |
| Aug 1, 2016 | $16M Series B | — | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, Kobi Marenko | Announced |
| Oct 1, 2014 | $6M Series A | — | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, Kobi Marenko | Announced |
| Jul 1, 2011 | $3M Seed | — | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, Kobi Marenko | Announced |
Sight Diagnostics is an Israeli medical-device company founded in 2010 that develops AI-driven, image-based blood diagnostic systems for rapid, point-of-care hematology testing.[1] Its flagship product, OLO, performs lab-grade complete blood counts (CBCs) and other tests from a finger-prick capillary blood sample using digital fluorescent microscopy and machine-learning algorithms, delivering results in minutes to serve outpatient clinics, urgent care centers, small hospitals, and resource-limited settings.[1] This addresses the problem of slow, centralized lab testing by enabling decentralized, convenient diagnostics, with the company showing growth through regulatory approvals (e.g., Health Canada), international partnerships, multiple funding rounds, and operations across the U.S., Europe, and Asia.[1]
Sight Diagnostics originated from early work on Parasight, a malaria diagnostic system leveraging the same imaging and AI technology, which was successfully deployed in multiple countries and proved the team's ability to commercialize machine-vision diagnostics for global health challenges.[1] Founded in 2010 in Tel Aviv, the company has evolved from this foundation into a broader hematology platform, expanding via product commercialization, geographic reach, and investor backing from firms like OurCrowd.[1][3] With a workforce of a few hundred employees, pivotal moments include OLO's development as a competitor to traditional lab analyzers and ongoing fundraising for international market entry.[1]
Sight Diagnostics rides the AI-in-healthcare trend, particularly in decentralizing diagnostics amid rising demand for rapid testing post-COVID and in telemedicine growth.[1] Timing aligns with advances in machine vision and edge AI, enabling portable devices that counter centralized lab bottlenecks, especially in underserved regions or high-volume outpatient care.[1] Market forces like aging populations, chronic disease prevalence, and global health initiatives favor it, as does competition from traditional analyzers creating opportunities for disruption.[1] The company influences the ecosystem by validating AI for hematology, paving the way for similar tech in other diagnostics and attracting investment into Israeli medtech.[1][3]
Sight Diagnostics is poised for accelerated growth through OLO commercialization, further regulatory wins (e.g., FDA expansion), and potential IPO amid pre-IPO interest.[1][4] Trends like AI integration in medtech, point-of-care expansion, and immune cell analysis (hinted in recent pivots) will shape its path, potentially evolving into broader immune signature platforms.[2] Its influence may grow by setting standards for AI diagnostics, tying back to its mission of fast, pain-free blood testing that transforms access to critical health insights.[1]
Sight Diagnostics has raised $149.0M in total across 6 funding rounds.
Sight Diagnostics's investors include Dan Eldar, 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko, Chase Koch, Eric Schmidt.